Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Lymphoma Clinical Trial

Official title:

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04263935
• Other study ID #: HNCH2019341
• Status: Recruiting
• Start date: January 3, 2019
• Est. completion date: December 2024

Study information

• Verified date: December 2023
• Source: Henan Cancer Hospital
• Contact: Yanyan Liu, M.D. Ph.D
• Phone: +8613818176375
• Email: yyliu[@]zzu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Description:

This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Diagnosed as lymphoma (according to WHO 2017 classification criteria)

2. Life expectancy no less than 3 months

3. Agreeing to sign the written informed consents

Exclusion Criteria:

1. Other malignant tumor history or active malignant tumor need be treated

2. Researchers determine unsuited to participate in this trial

Related Conditions & MeSH terms

• Congenital Abnormalities
• Gene Abnormality
• Lymphoma

Locations

Country	Name	City	State
China	Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of driver gene abnormalities	the incidence of driver gene abnormalities by fixed gene testing technology	from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months
Secondary	objective response rate	the total proportion of patients with complete response (CR) and partial response (PR)	from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
Secondary	5-year overall survival	from the date of first patient was included to the date of death by any cause	from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years
Secondary	Clinicopathological Characteristics	study data on clinicopathological characteristics related to incidence of driver gene abnormalities	from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months